◼ Archived
Health
A precision T-cell therapy stalls treatment-resistant cancers in clinical trial
Marengo Therapeutics' Invikafusp alfa shows promise in treating TMB-H solid tumors resistant to standard immune checkpoint blockade.
4 trends tracked about this subject — the full history, oldest to newest below.
Marengo Therapeutics' Invikafusp alfa shows promise in treating TMB-H solid tumors resistant to standard immune checkpoint blockade.
UCLA scientists have developed a method to convert cord blood into powerful T cells designed to fight solid-tumor cancers at a cost of $5,000.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Four children with terminal brain cancer are surviving years after undergoing a breakthrough experimental autologous T cell therapy.